| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
584.78(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.22 - $11.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 245 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
| Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
| Total People Sold |
1 |
2 |
2 |
4 |
| Total Sell Transactions |
1 |
3 |
11 |
21 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sabesan Vijay |
SVP, Technical Operations |
• – – |
2021-02-20 |
4 |
D |
$18.79 |
$156,765 |
D/D |
(8,343) |
249,701 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
170,000 |
1,445,169 |
|
- |
|
| Brady Ann |
President, TBIL |
• – – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
138,287 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
316,916 |
|
- |
|
| Hindman Andrew A. |
SVP, Chief Financial Officer |
• – – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
188,688 |
|
- |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
258,044 |
|
- |
|
| Graham Richard A |
SVP, Development |
• – – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
188,749 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
400,280 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Business Officer |
• – – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
466,680 |
|
- |
|
| Worboys Philip D |
SVP, Research & Transl Science |
• – – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
384,395 |
|
- |
|
| Graham Richard A |
SVP, Development |
• – – |
2020-12-14 |
4 |
S |
$19.47 |
$146,058 |
D/D |
(7,500) |
123,749 |
|
-9% |
|
| Worboys Philip D |
SVP, Research & Transl Science |
• – – |
2020-12-03 |
4 |
S |
$18.00 |
$76,428 |
D/D |
(4,246) |
319,395 |
|
-25% |
|
| Brady Ann |
President, TBIL |
• – – |
2020-11-20 |
4 |
D |
$17.21 |
$39,445 |
D/D |
(2,292) |
98,287 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2020-11-20 |
4 |
D |
$17.21 |
$82,728 |
D/D |
(4,807) |
335,280 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2020-11-20 |
4 |
D |
$17.21 |
$82,728 |
D/D |
(4,807) |
251,916 |
|
- |
|
| Graham Richard A |
SVP, Development |
• – – |
2020-11-20 |
4 |
D |
$17.21 |
$66,706 |
D/D |
(3,876) |
131,249 |
|
- |
|
| Sabesan Vijay |
SVP, Technical Operations |
• – – |
2020-11-20 |
4 |
D |
$17.21 |
$65,364 |
D/D |
(3,798) |
193,044 |
|
- |
|
| Worboys Philip D |
SVP, Research & Transl Science |
• – – |
2020-11-20 |
4 |
D |
$17.21 |
$82,728 |
D/D |
(4,807) |
323,641 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2020-11-20 |
4 |
D |
$17.21 |
$72,523 |
D/D |
(4,214) |
401,680 |
|
- |
|
| Haumann Brett K |
Chief Medical Officer |
• – – |
2020-11-20 |
4 |
D |
$17.21 |
$79,837 |
D/D |
(4,639) |
278,171 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2020-11-20 |
4 |
D |
$17.21 |
$240,011 |
D/D |
(13,946) |
1,275,169 |
|
- |
|
| Graham Richard A |
SVP, Development |
• – – |
2020-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
135,125 |
|
- |
|
| Haumann Brett K |
Chief Medical Officer |
• – – |
2020-08-21 |
4 |
S |
$18.29 |
$457,240 |
D/D |
(25,000) |
282,810 |
|
8% |
|
| Graham Richard A |
SVP, Development |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$120,216 |
D/D |
(6,598) |
107,625 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2020-08-20 |
4 |
D |
$18.22 |
$76,779 |
D/D |
(4,214) |
405,894 |
|
- |
|
529 Records found
|
|
Page 7 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.03 (0.33%) 
